Congress conducts hearing on DTC advertising

Share this article:
The House Energy and Commerce Committee is scheduled to conduct a hearing on DTC advertising on May 8, beginning at 10 a.m.

The committee is chaired by Congressman Bart Stupak, a Michigan Democrat and fierce critic of the industry who has previously called for the resignation of FDA commissioner Andrew von Eschenbach.

Among those expected to testify at the hearing are: Nancy Nielsen, president elect of the American Medical Association; Mollyann Brodie, VP and director public opinion and media research at the Kaiser Family Foundation; Marcia Crosse, director health care, US Government Accountability Office; James Sage, senior director/team leader, Lipitor at Pfizer; Deepak Khanna, SVP and general manager Merck/Schering Plough; and Kim Taylor, president Ortho Biotech. 

For more information, or to watch a live webcast of the hearing, log on to: http://energycommerce.house.gov/membios/schedule.shtml
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...